Literature DB >> 26303589

Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review.

Wenge Wang1, Jihua Cheng2, Carol Mallon2, Mohammed Y Al-Marrawi2, Sheldon Holder2, Monika Joshi2, Matthew Kaag2, Giampaolo Talamo2, Joseph J Drabick2.   

Abstract

Entities:  

Keywords:  Axitinib; Bevacizumab; Erythropoietin; Hypoxia induced factor; Pazopanib; Phlebotomy; Sorafenib; Tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2015        PMID： 26303589     DOI： 10.1016/j.clgc.2015.07.003

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  2 in total

1.  Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma.

Authors:  Nedal Bukhari; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2017-11       Impact factor: 1.862

2.  Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.

Authors:  Alison C Johnson; Margarida Matias; Helen Boyle; Bernard Escudier; Alicia Molinier; Brigitte Laguerre; Carole Helissey; Pierre-Emmanuel Brachet; Audrey Emmanuelle Dugué; Loic Mourey; Elodie Coquan; Florence Joly
Journal:  BMC Cancer       Date:  2017-05-22       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.